BMS-986368 for muscle tightness after stroke compared with placebo
Tests BMS-986368 for muscle tightness in adults who have had a stroke.
Plain-language title generated from the registry record
Registry title: A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)
Key facts
- Where
- Elkins Park, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07704840, who can take part
Where in United States
- Jeffersi=on Moss Magee RehabilitationElkins Park, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alberto Esquenazi
- Trial code
- NCT07704840
- Record updated
- 1 October 2026
- Original description
The goal of this clinical trial is to learn if the drug BMS-986368 works to treat post stroke spasticity in adults who have had a stroke. BMS-986368 is a designed to increase natural compounds in the body that may help calm nerves that cause muscles to be tight or spasm. The study will also learn about the safety of drug BMS-986368Read full original descriptionShow less
A Phase 2, Randomized, Double-blind, Placebo-controlled Pilot Study Assessing the Efficacy, Safety and Tolerability of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Post-stroke Spasticity
The goal of this clinical trial is to learn if the drug BMS-986368 works to treat post stroke spasticity in adults who have had a stroke. BMS-986368 is a designed to increase natural compounds in the body that may help calm nerves that cause muscles to be tight or spasm. The study will also learn about the safety of drug BMS-986368
Inclusion: Ischemic or hemorrhagic stroke diagnosis 4 to 18 months prior to enrollment; History of post stroke spasticity for at least 2 months prior to Screening Visit; Modified Ashworth Scale (mAS) score ≥2 and <4 for affected elbow and wrist joints at Screen and Baseline Visits; Fugl-Meyer Assessment for Upper Extremity (FMA-UE) greater than 22 at Screen and Baseline Visits; Willing to participate with no therapy additions during study duration; Participant must be able to read, speak, and understand English usage.
Exclusion: Participants must not have any concomitant disease or disorder that has symptoms of spasticity or that may influence the participant's level of spasticity; Participants must not be currently taking a medication for spasticity that cannot be discontinued and washed out prior to randomization; Participants must not have used FAAH/MAGL inhibitor medication or any cannabinoid-related products (including cannabis, cannabidiol (CBD), or tetrahydrocannabinol (THC)) within 30 days prior to randomization; Participants must not have a history of any substance abuse disorder as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Diagnostic Criteria for Drug and Alcohol Abuse; Individuals who are pregnant or breastfeeding; Other protocol-defined Inclusion/Exclusion criteria apply.